ozenoxacin

oz-en-OX-a-sin

Therapeutic Classification: anti-infectives

Pharmacologic Classification: Fluoroquinolones

REMS

Inhibits bacterial DNA synthesis by inhibiting DNA gyrase A and topoisomerase IV.

Therapeutic effects:

Spectrum:

Active against gram-positive pathogens, including:
- Staphylococcus aureus
- Streptococcus pyogenes.

Absorption: Minimal systemic absorption.

Distribution: Not applicable because of minimal systemic absorption.

Metabolism/Excretion: Not applicable because of minimal systemic absorption.

Half-Life: Not applicable because of minimal systemic absorption.

ROUTE	ONSET	PEAK	DURATION
Topical	n/a	n/a	n/a

Contraindicated in:

Use Cautiously in:

OB: Safety not established; fetal exposure not expected due to minimal systemic absorption;
Pedi: Children 2 mo (safety and effectiveness not established).

Derm: rosacea, seborrheic dermatitis

Drug-drug:

(Adults and Children ≥2 mo): Apply to affected area twice daily for 5 days.

Apply a thin layer to affected area twice daily for five days. Wash hands after application. May cover treated area with sterile bandage or gauze dressing. Not for oral, ophthalmic, intranasal, or intravaginal use.

Instruct patient or parent in correct technique for application and to apply only in treatment area. Advise patient or parent to wash hands following application. Instruct patient or parent to use ozenoxacin for entire prescribed time, even if symptoms improved.
Advise patient or parent to notify health care professional is no improvement is seen after 3 days of therapy.

Xepi